Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian CancerGlobeNewsWire • 02/06/23
GENE to Launch World's First Comprehensive Risk Test for Breast & Ovarian CancerGlobeNewsWire • 02/03/23
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of GrowthGlobeNewsWire • 01/30/23
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetesGlobeNewsWire • 12/06/22
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar DetailsGlobeNewsWire • 10/25/22
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 10/13/22
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancerGlobeNewsWire • 09/29/22
Completion of AffinityDNA Acquisition expanding global direct-to-consumer businessGlobeNewsWire • 07/14/22
Genetic Technologies Limited (GENE) CEO Simon Morriss on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/21/22
Genetic Technologies drives leadership in precision medicine with Multi-Risk TestGlobeNewsWire • 04/08/22
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/14/22
GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/10/21
Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTOGlobeNewsWire • 12/09/21
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 Fiscal Year 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21